Trial Profile
2 Part, Phase II Study of Intravenous, Single Ascending Dose Administrations of IOP Injection in Patients With Iron Deficient Anemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Iron oxide-PEG (Primary) ; Dextran sulfate
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Sponsors Megapro Biomedical Company
- 21 Oct 2021 Status changed from active, no longer recruiting to discontinued.
- 24 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Aug 2021.
- 24 Nov 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2020.